Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3275MR)

This product GTTS-WQ3275MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3275MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6145MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ13392MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ10386MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ1637MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ9440MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ3882MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ2532MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ13770MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW